257 related articles for article (PubMed ID: 24370624)
1. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods.
Werk T; Volkin DB; Mahler HC
Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624
[TBL] [Abstract][Full Text] [Related]
2. Measuring Subvisible Particles in Protein Formulations Using a Modified Light Obscuration Sensor with Improved Detection Capabilities.
Ríos Quiroz A; Québatte G; Stump F; Finkler C; Huwyler J; Schmidt R; Mahler HC; Koulov AV; Adler M
Anal Chem; 2015 Jun; 87(12):6119-24. PubMed ID: 26001042
[TBL] [Abstract][Full Text] [Related]
3. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging.
Sharma DK; Oma P; Pollo MJ; Sukumar M
J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937
[TBL] [Abstract][Full Text] [Related]
4. Label-free flow cytometry analysis of subvisible aggregates in liquid IgG1 antibody formulations.
Nishi H; Mathäs R; Fürst R; Winter G
J Pharm Sci; 2014 Jan; 103(1):90-9. PubMed ID: 24218205
[TBL] [Abstract][Full Text] [Related]
5. Quantitation of protein particles in parenteral solutions using micro-flow imaging.
Huang CT; Sharma D; Oma P; Krishnamurthy R
J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372
[TBL] [Abstract][Full Text] [Related]
6. Variance Between Different Light Obscuration and Flow Imaging Microscopy Instruments and the Impact of Instrument Calibration.
Matter A; Koulov A; Singh S; Mahler HC; Reinisch H; Langer C; Zucol B; Mathaes R
J Pharm Sci; 2019 Jul; 108(7):2397-2405. PubMed ID: 30844365
[TBL] [Abstract][Full Text] [Related]
7. Critical evaluation and guidance for using the Coulter method for counting subvisible particles in protein solutions.
Barnard JG; Rhyner MN; Carpenter JF
J Pharm Sci; 2012 Jan; 101(1):140-53. PubMed ID: 22109687
[TBL] [Abstract][Full Text] [Related]
8. How subvisible particles become invisible-relevance of the refractive index for protein particle analysis.
Zölls S; Gregoritza M; Tantipolphan R; Wiggenhorn M; Winter G; Friess W; Hawe A
J Pharm Sci; 2013 May; 102(5):1434-46. PubMed ID: 23463514
[TBL] [Abstract][Full Text] [Related]
9. Quantification and characterization of micrometer and submicrometer subvisible particles in protein therapeutics by use of a suspended microchannel resonator.
Patel AR; Lau D; Liu J
Anal Chem; 2012 Aug; 84(15):6833-40. PubMed ID: 22794526
[TBL] [Abstract][Full Text] [Related]
10. Collaborative Study for Analysis of Subvisible Particles Using Flow Imaging and Light Obscuration: Experiences in Japanese Biopharmaceutical Consortium.
Kiyoshi M; Shibata H; Harazono A; Torisu T; Maruno T; Akimaru M; Asano Y; Hirokawa M; Ikemoto K; Itakura Y; Iwura T; Kikitsu A; Kumagai T; Mori N; Murase H; Nishimura H; Oda A; Ogawa T; Ojima T; Okabe S; Saito S; Saitoh S; Suetomo H; Takegami K; Takeuchi M; Yasukawa H; Uchiyama S; Ishii-Watabe A
J Pharm Sci; 2019 Feb; 108(2):832-841. PubMed ID: 30121316
[TBL] [Abstract][Full Text] [Related]
11. Particle shape effects on subvisible particle sizing measurements.
Cavicchi RE; Carrier MJ; Cohen JB; Boger S; Montgomery CB; Hu Z; Ripple DC
J Pharm Sci; 2015 Mar; 104(3):971-87. PubMed ID: 25446188
[TBL] [Abstract][Full Text] [Related]
12. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation.
Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB
J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596
[TBL] [Abstract][Full Text] [Related]
13. Shape Characterization of Subvisible Particles Using Dynamic Imaging Analysis.
Mathaes R; Manning MC; Winter G; Engert J; Wilson GA
J Pharm Sci; 2020 Jan; 109(1):375-379. PubMed ID: 31476311
[TBL] [Abstract][Full Text] [Related]
14. A critical review of analytical methods for subvisible and visible particles.
Narhi LO; Jiang Y; Cao S; Benedek K; Shnek D
Curr Pharm Biotechnol; 2009 Jun; 10(4):373-81. PubMed ID: 19519412
[TBL] [Abstract][Full Text] [Related]
15. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods.
Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051
[TBL] [Abstract][Full Text] [Related]
16. Backgrounded Membrane Imaging (BMI) for High-Throughput Characterization of Subvisible Particles During Biopharmaceutical Drug Product Development.
Helbig C; Ammann G; Menzen T; Friess W; Wuchner K; Hawe A
J Pharm Sci; 2020 Jan; 109(1):264-276. PubMed ID: 30914272
[TBL] [Abstract][Full Text] [Related]
17. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis.
Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K
Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466
[TBL] [Abstract][Full Text] [Related]
18. Calculating the mass of subvisible protein particles with improved accuracy using microflow imaging data.
Kalonia C; Kumru OS; Prajapati I; Mathaes R; Engert J; Zhou S; Middaugh CR; Volkin DB
J Pharm Sci; 2015 Feb; 104(2):536-47. PubMed ID: 25302696
[TBL] [Abstract][Full Text] [Related]
19. Imaging Flow Cytometry for Sizing and Counting of Subvisible Particles in Biotherapeutics.
Helbig C; Menzen T; Wuchner K; Hawe A
J Pharm Sci; 2022 Sep; 111(9):2458-2470. PubMed ID: 35777484
[TBL] [Abstract][Full Text] [Related]
20. Viscosity of aqueous DNA solutions determined using dynamic light scattering.
Gilroy EL; Hicks MR; Smith DJ; Rodger A
Analyst; 2011 Oct; 136(20):4159-63. PubMed ID: 21869949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
